http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
다발골수종의 Cyclophosphamide 및 Prednisone 복합화학요법의 효과
유미라 ( Mi Ra You ),임현종 ( Hyun Jong Lim ),이희정 ( Hee Jeong Lee ),김형호 ( Hyung Ho Kim ),문우람 ( Woo Ram Moon ),정춘해 ( Choon Hae Chung ),박치영 ( Chi Young Park ),박상곤 ( Sang Gon Park ) 대한내과학회 2013 대한내과학회지 Vol.84 No.5
Background/Aims: For many years, conventional treatment for multiple myeloma (MM) not ineligible for high-dose therapy has been the combination of oral melphalan and prednisone (MP). However, melphalan-based regimens are associated with numerous complications. Another alkylating agent, cyclophosphamide, has similar effects on MM and is associated with fewer reports of complications. Therefore, cyclophosphamide-based regimens have usually been used as salvage therapy in patients with refractory or relapsed MM, despite the development of newer drugs. The purpose of this report was to evaluate the efficacy and tolerability of cyclophosphamide and prednisone as a first-line therapy for MM. Methods: For the period January 2002 to June 2012, we retrospectively analyzed 29 patients newly diagnosed with MM who underwent a treatment regimen consisting of intravenous cyclophosphamide (1,000 mg/kg) for 1 day and prednisone (100 mg) for 4 days. Results: The rate of response to this regimen was 31.1 percent. The median progression-free survival (PFS) was 5.5 months and the median overall survival (OS) was 47.3 months. The regimen was well tolerated. Adverse effects of grades above III were as follows: anemia in seven patients (24.1%), neutropenia in five patients (17.2%), and thrombocytopenia in two patients (6.8%). These adverse effects were easily adjusted. No one developed a secondary malignancy or hemorrhagic cystitis. Conclusions: Although PFS was less than for the MP regimen, median OS was better than for the MP regimen. Furthermore, the cyclophosphamide-prednisone regimen was well tolerated, and the adverse effects that did occur were easily adjusted. The cyclophosphamide-prednisone combination regimen may represent an effective and well tolerated first-line therapy for non-transplant candidates with MM. (Korean J Med 2013; 84:690-697)
최성형 ( Seong Hyung Choi ),김현숙 ( Hyun Sook Kim ),유미라 ( Mi Ra You ),김만우 ( Man Woo Kim ) 대한류마티스학회 2010 대한류마티스학회지 Vol.17 No.1
Dermatomyositis is a distinctive entity that is identified by a characteristic rash that accompanies or more often precedes proximal muscle weakness. There is a well recognized association between dermatomyositis and several cancers, such as ovarian cancer, lung cancer, pancreas cancer, stomach cancer and colorectal cancers and non-Hodgkin Lymphoma. But dermatomyositis associated with intrahepatic cholangiocarcinoma has not yet been reported in Korea. We experienced a case of dermatomyositis associated with infiltrative intrahepatic cholangiocarcinoma and we report on this unusual case along with reviewing the related literature.
혈전성 혈소판감소성 자반증으로 발현된 전신홍반루푸스 1예
오명근,유미라,변유미,윤찬영,권세훈,박치영,김상현 朝鮮大學校 附設 醫學硏究所 2007 The Medical Journal of Chosun University Vol.32 No.3
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening syndrome characterized by the classic pentad of clinical features that includes microangiopathic hemolytic anemia, thrombocytopenia, neurologic abnormalities, fever, and renal dysfunction. Early diagnosis and utilization of plasmapheresis can improve the survival rates of patients with TTP. TTP rarely may be seen in association with autoimmune disease such as systemic lupus erythematous (SLE). We report here a 42-year-old female who was presented with severe digital gangrenes, microangiopathic hemolytic anemia, thrombocytopenia, neurologic abnormalities, fever, and renal dysfunction. Her condition responded to combined therapy with high dose steroid, immunosuppressants, and plasmapheresis therapy.